PRINCETON, NJ - Sonnet BioTherapeutics Holdings ... with a target enrollment of up to 18 patients. The primary outcome measures include safety, tolerability, pharmacokinetics, and pharmacodynamics ...

Session: Poster Session B Abstract title:Combination immunotherapy with an albumin-binding interleukin-12 fusion protein that extends cytokine half-life, targets the tumor microenvironment, and ...